- Q1 2024 Photocure ASA Earnings Call TranscriptMay 15, 2024$5.95Earnings
- Q4 2023 Photocure ASA Earnings Call TranscriptFeb 21, 2024$6.5Earnings
- Q3 2023 Photocure ASA Earnings Call TranscriptNov 08, 2023$5Earnings
- Q2 2023 Photocure ASA Earnings Call TranscriptAug 09, 2023$4.75Earnings
- Q1 2023 Photocure ASA Earnings Call TranscriptMay 10, 2023$10.85Earnings
- Q4 2022 Photocure ASA Earnings Call TranscriptFeb 23, 2023$10.85Earnings
- Q3 2022 Photocure ASA Earnings Call TranscriptNov 02, 2022$10.13Earnings
- Q2 2022 Photocure ASA Earnings Presentation TranscriptAug 10, 2022
- Q1 2022 Photocure ASA Earnings Presentation TranscriptMay 11, 2022
- Photocure ASA at Needham Healthcare Conference (Virtual) TranscriptApr 14, 2022
- Q4 2021 Photocure ASA Earnings Presentation TranscriptFeb 23, 2022
- Q3 2021 Photocure ASA Earnings Call TranscriptNov 17, 2021$12.25Earnings
- Q2 2021 Photocure ASA Earnings Call TranscriptAug 11, 2021$15.87Earnings
- Photocure ASA Annual Shareholders Meeting TranscriptMay 20, 2021
- Q1 2021 Photocure ASA Earnings Presentation TranscriptMay 19, 2021
- Q4 2020 Photocure ASA Earnings Call TranscriptMar 03, 2021$14Earnings
- Q3 2020 Photocure ASA Earnings Call TranscriptNov 10, 2020$8.01Earnings
- Q2 2020 Photocure ASA Earnings Call TranscriptAug 18, 2020$7.15Earnings
- Photocure ASA Annual Shareholders Meeting TranscriptJun 10, 2020
- Q1 2020 Photocure ASA Earnings Call TranscriptMay 07, 2020$6.8Earnings
- Q4 2019 Photocure ASA Earnings Call TranscriptFeb 27, 2020$9.75Earnings
- Q3 2019 Photocure ASA Earnings Call TranscriptNov 07, 2019$6.35Earnings
- Q2 2019 Photocure ASA Earnings Call TranscriptAug 07, 2019$6.5Earnings
- Q1 2019 Photocure ASA Earnings Call TranscriptMay 14, 2019$4.85Earnings
Q3 2021 Photocure ASA Earnings Call Transcript
Well, good afternoon to those in Europe. Good morning. This is Dan Schneider, CEO of Photocure. With me today is Erik Dahl, CFO, and we're proud to present the results for the third quarter of 2021.
Next slide. Just a reminder, today's disclaimers are in place.
Third slide. So I believe we delivered another productive quarter in the shadows of COVID. We've shown growth. We continue to generate data on the advantages of using blue light cystoscopy. We strengthened partnerships and entered new markets like Canada, and we ended the quarter with a strong balance sheet.
Keep in mind, a couple of important factors. Last year's Q3 was a catch-up quarter for postponed procedures in quarter two. So we're up against an inordinate amount of backlog that hit Q3 last year. And this year, we dealt with the onslaught of the delta variant as we got into Q3. However, we did show growth in many markets like the U.S., France, Italy, U.K. and held tight on some of the other markets like Germany. We are essentially breakeven and demonstrated
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)